NCT04305067 is a NA clinical trial of Exercise in Pancreas Adenocarcinoma, sponsored by Queen's University, Belfast.

Who is sponsoring NCT04305067?

NCT04305067 is sponsored by Queen's University, Belfast.

What drugs are being tested in NCT04305067?

Interventions in NCT04305067: Exercise.

What condition does NCT04305067 study?

NCT04305067 studies Pancreas Adenocarcinoma.

Is NCT04305067 still recruiting?

NCT04305067 is currently completed. Last updated 16 February 2024.

Last reviewed 2024-02-16 · How we verify

NCT04305067

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRECISE: Pancreatic Cancer and Exercise

Completed NA Last updated 16 February 2024

What this trial tests

NA trial testing Exercise in Pancreas Adenocarcinoma in 8 participants. Completed in 1 August 2022.

Timeline

1 August 2020

Primary endpoint
31 July 2022

1 August 2022

Quick facts

Lead sponsor	Queen's University, Belfast
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	8
Start date	1 August 2020
Primary completion	31 July 2022
Estimated completion	1 August 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

Exercise

Conditions studied

Pancreas Adenocarcinoma — all drugs for Pancreas Adenocarcinoma →

Sponsor

Queen's University, Belfast

Who can join

18 and older, any sex, with Pancreas Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish the feasibility of delivering a prescribed, individualised supervised aerobic and resistance exercise programme during adjuvant therapy, to improve survival and reduce symptom burden in pancreatic cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A review of physical activity in pancreatic ductal adenocarcinoma: Epidemiology, intervention, animal models, and clinical trials.
Hsueh HY, Pita-Grisanti V, Gumpper-Fedus K, Lahooti A, et al · · 2022 · cited 17× · PMID 34750076 · DOI 10.1016/j.pan.2021.10.004
Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series.
Brown M, O'Connor D, Turkington R, Eatock M, et al · · 2023 · cited 2× · PMID 37735664 · DOI 10.1186/s13102-023-00722-3

Verify or expand the search:

Other trials of Exercise

Trials testing the same drug.

NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
NCT07589725 — Mulligan Mobilization in Lateral Elbow Tendinopathy · NA · not yet recruiting
NCT07524400 — Effects of Physical Exercise Combined With Transcranial Direct Current Stimulation in Parkinson's Disease · NA · recruiting
NCT06627569 — Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans · NA · not yet recruiting

Other recruiting trials for Pancreas Adenocarcinoma

Currently open trials in the same condition.

NCT07043270 — 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC · Phase 2 · recruiting
NCT07262957 — Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Inc · Phase 4 · recruiting
NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
NCT07022015 — Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy · NA · recruiting
NCT06497777 — The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of · recruiting

Other Queen's University, Belfast trials

Trials by the same sponsor.

NCT07373041 — Heart Failure Carer Support Programme: Implementation Testing in the UK. · NA · not yet recruiting
NCT07482839 — Feasibility Study of a Compassionate Mindful Resilience (CMR) Intervention to Improve Mental Health Well-being Outcomes · NA · not yet recruiting
NCT07333924 — Randomised Study Within a Review (SWAR) to Compare Communication of the Findings of Systematic Reviews to the Public by · Phase 3 · completed
NCT06896799 — Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM) · NA · recruiting
NCT06749327 — Dissecting the Roles of High-quality Diets and Ultra Processed Foods on Cardiometabolic Health · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04305067 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen's University, Belfast
Last refreshed: 16 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04305067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing